Gottlieb Attacks Plans Again For High Drug Costs

April 13, 2018
FDA Commissioner Scott Gottlieb again attacked plans for high drug costs, and he honed his explanation for taking on policies under CMS’ purview. “The FDA is taking an interest in this problem because, although we don’t regulate drug prices, if anticompetitive forces and profit taking across the drug supply chain are pushing effective treatments out of the reach of patients, the full benefits of innovation to improve public health are not being realized,” according to Gottlieb’s prepared remarks at a...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.